Jacqueline Gibbons
About Jacqueline Gibbons
Jacqueline Gibbons is the Senior Vice President at Nektar Therapeutics, where she has worked since 2019. She has extensive experience in clinical pharmacology and has contributed to the development of significant oncology products, including enzalutamide (Xtandi).
Work at Nektar Therapeutics
Jacqueline Gibbons has served as Senior Vice President at Nektar Therapeutics since 2019. In this role, she contributes to the strategic direction and leadership of the organization, which is based in the San Francisco Bay Area. Her extensive experience in clinical pharmacology and drug development supports Nektar's mission to advance innovative therapies.
Previous Positions in the Pharmaceutical Industry
Prior to her current role, Gibbons held several significant positions in the pharmaceutical industry. She was Vice President at Achaogen from 2017 to 2019 and served as Executive Director of Clinical Pharmacology at Jazz Pharmaceuticals from 2016 to 2017. Additionally, she worked at Medivation as Senior Director of Clinical Pharmacology & DMPK from 2008 to 2016 and at Bayer in Bioanalytics and PK from 1998 to 2000.
Education and Expertise
Jacqueline Gibbons earned her Ph.D. in Toxicology from Cornell University and holds a Bachelor's degree in Biology from UC Berkeley. Her educational background provides a strong foundation for her expertise in pharmacokinetics, drug metabolism, and bioanalytics, which are critical in her roles throughout her career.
Research and Publications
Gibbons has published extensively on topics related to clinical and nonclinical studies of pharmacokinetics, drug metabolism and pharmacokinetics (DMPK), and bioanalytics. Her research contributions have advanced understanding in these fields and supported the development of various therapeutic products.
Achievements in Clinical Pharmacology
Gibbons has a notable track record in clinical pharmacology, including serving as the lead clinical pharmacologist for enzalutamide (Xtandi). This oncology product has been approved in over 50 countries and generates approximately 2 billion dollars in annual sales. She was responsible for overseeing the clinical pharmacology program and postmarketing studies for this significant therapeutic agent.